Correction to Lancet Neurol 2022; 21: 1099-109
- PMID: 36804096
- DOI: 10.1016/S1474-4422(23)00048-0
Correction to Lancet Neurol 2022; 21: 1099-109
Erratum for
-
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8. Lancet Neurol. 2022. PMID: 36402160 Clinical Trial.
Similar articles
-
Correction to Lancet Neurol 2022; 21: 284-94.Lancet Neurol. 2022 Oct;21(10):e9. doi: 10.1016/S1474-4422(22)00376-3. Lancet Neurol. 2022. PMID: 36115366 No abstract available.
-
Correction to Lancet Neurol 2022; 21: 682-86.Lancet Neurol. 2022 Sep;21(9):e8. doi: 10.1016/S1474-4422(22)00313-1. Lancet Neurol. 2022. PMID: 35963266 No abstract available.
-
Correction to Lancet Neurol 2022; 21: 620-31.Lancet Neurol. 2022 Jul;21(7):e7. doi: 10.1016/S1474-4422(22)00229-0. Lancet Neurol. 2022. PMID: 35716697 No abstract available.
-
Epidemiology and cultural differences in tension-type headache.Curr Pain Headache Rep. 2012 Dec;16(6):525-32. doi: 10.1007/s11916-012-0296-5. Curr Pain Headache Rep. 2012. PMID: 22948318 Review.
-
Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease.Neurol Sci. 2012 Feb;33(1):201-8. doi: 10.1007/s10072-011-0825-8. Epub 2011 Nov 5. Neurol Sci. 2012. PMID: 22057264
Publication types
LinkOut - more resources
Full Text Sources